{"url_path":"/sec/crbp/8-k/2026-05-21/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1595097/0001193125-26-233507-index.html","accession_number":"0001193125-26-233507","cik":"0001595097","ticker":"CRBP","issuer_name":"Corbus Pharmaceuticals Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1595097/0001193125-26-233507-index.html","primary_entity_key":"0001595097","primary_entity_name":"Corbus Pharmaceuticals Holdings, Inc."},"word_count":135,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn May 21, 2026, the Company issued a press release announcing the appointment of Mr. Saxena as Chief Business Officer of the Company, and that the Company’s management team will host a conference call and webcast on Tuesday, May 26, 2026 at 8:00 a.m. EDT to discuss clinical data from its Phase 1/2 study of CRB-701. A copy of the press release is furnished as Exhibit 99.1 hereto and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing."}